Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CET
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at [email protected] and Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN 2.80% 292.78 Delayed Quote.-10.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
02/19Rare Haematology Market Trend to 2025 Profiling PRA Health Sciences, Bayer He..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/15BIOGEN : Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Is..
AQ
02/15BIOGEN : slips on Phase III AD studies
AQ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/12BIOGEN : Norway to buy Biogen's Spinraza medicine - broadcaster NRK
RE
02/12American College of Rheumatology recommends biosimilars for rheumatic disease
AQ
02/09BIOGEN : Stake Increased by Factory Mutual Insurance Co.
AQ
02/07BIOGEN : to Present at the Leerink Partners 7th Annual Global Healthcare Confere..
AQ
More news
News from SeekingAlpha
02/22Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2017 Update 
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Biogen chief says market overreacted to increased enrollment in aducanumab st.. 
02/19VALUATION DASHBOARD : Healthcare - Update 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
Financials ($)
Sales 2018 13 009 M
EBIT 2018 6 975 M
Net income 2018 4 617 M
Debt 2018 436 M
Yield 2018 -
P/E ratio 2018 12,82
P/E ratio 2019 12,18
EV / Sales 2018 4,69x
EV / Sales 2019 4,12x
Capitalization 60 528 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 381 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-10.60%60 528
CSL LIMITED12.05%55 872
ALEXION PHARMACEUTICALS-2.08%25 959
GRIFOLS SA-4.03%18 247
BIOMARIN PHARMACEUTICAL-5.56%14 752
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 682